Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)

• click to rate

  Posted by Two Blokes Jun 12 - Filed in Stock - 5 views
  
  Zymeworks Inc.'s lead asset zanidatamab won FDA approval for HER2-positive biliary tract cancer, validating its platform but addressing a small market. The main investment thesis hinges on upcoming Phase 3 data for zanidatamab in first-line HER2-positive gastroesophageal adenocarcinoma, a much larger opportunity. Partnerships with Jazz and BeiGene provide non-dilutive funding and milestone payments, but limit Zymeworks' upside to royalties and milestones.